CoreRx, Inc. Increasing Capacity With Construction of Third Facility
CoreRx, Inc. recently announced plans for expansion of its manufacturing capabilities in Clearwater, FL. The expansion will introduce a third facility to include additional R&D laboratories, warehouse, manufacturing, and office space, while adding approximately 25 additional employees to the Clearwater workforce over time.
“This project represents a significant expansion in both the size and mission of CoreRx,” said Brian McMillan, Vice President and CTO.
“We continue to see Pinellas County as a center of excellence for the development and manufacture of pharmaceutical products, optimally organized to support our client’s never-ending and growing pipeline of investigational medicines and potential new medicines,” added Mark Licarde the company’s VP and COO.
The Myerlake III site will add approximately 45,000 sq ft of additional R&D, manufacturing, warehouse, and office space. CoreRx plans to begin construction in the buildings adjacent to its current facilities in the ICOT center campus. It will house five additional suites dedicated to Process Development, where investigational medicines will be formulated to support clinical trials.
Construction of the current CoreRx (Myerlake I) site was completed in July 2012. The Myerlake I site also was designed to accommodate future expansion, and the decision to expand reflects both the initial success of CoreRx and some of the factors that first drew them to build in this area. These include the increasing abundance of biotechnology knowledge, education, and training in the Tampa area, which is well on its way to creating a large and well-qualified workforce, as well as the inception of the USF College of Pharmacy, of which the founding members of CoreRx are an integral part. Work on the expansion is began earlier this month and the work should be completed by the middle of Q1 2016.
CoreRx is a contract research organization providing customized preformulation services, formulation development, manufacturing, and analytical services to pharmaceutical, biotechnology, academic, and veterinary clients. The company is renowned for reliably expediting early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. CoreRx’s unique corporate structure creates project teams that work intensively with each client, bringing an extension of its own organization into the CoreRx lab.
As a fully cGMP contract facility, CoreRx provides formulation development, analytical, and clinical material resources, utilizing a variety of multi-layer tablet equipment for combination products. CoreRx also offers development and manufacture of multiparticulate combination drug products. For more information, visit www.corerxpharmqa.com.
Total Page Views: 1110
